Risks of cardiovascular toxicities associated with ALK tyrosine kinase inhibitors in patients with non-small-cell lung cancer: a meta-analysis of randomized control trials.
Sign Up to like & getrecommendations! Published in 2023 at "Expert opinion on drug safety"
DOI: 10.1080/14740338.2023.2182284
Abstract: BACKGROUND Anaplastic lymphoma kinases (ALK) tyrosine kinase inhibitors (TKIs) are targeted therapies used in advanced ALK-positive non-small cell lung cancers (NSCLC) which showed excellent efficacy and safety. However, ALK TKIs-associated cardiovascular toxicities [cardiac disorders, venous… read more here.
Keywords: meta analysis; toxicities associated; cardiovascular toxicities; alk tkis ... See more keywords
A comprehensive clinical evaluation of first-line drugs for ALK-positive advanced non-small cell lung cancer
Sign Up to like & getrecommendations! Published in 2023 at "Journal of Thoracic Disease"
DOI: 10.21037/jtd-23-380
Abstract: Background Anaplastic lymphoma kinase-tyrosine kinase inhibitors (ALK-TKIs) are mainly used in the treatment of ALK-positive advanced non-small cell lung cancer (NSCLC), but a comprehensive clinical evaluation of ALK-TKIs is lacking. Hence, a comparison of ALK-TKIs… read more here.
Keywords: comprehensive clinical; evaluation; alk; positive advanced ... See more keywords
Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Associated Cardiotoxicity: A Recent Five-Year Pharmacovigilance Study
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2022.858279
Abstract: Background: Clinical trials frequently reported anaplastic lymphoma kinase tyrosine kinase inhibitors (ALK-TKIs) associated with cardiac adverse drug events (AEs) but minimal postmarketing data. We aimed to research real-world cardiac disorders associated with ALK-TKIs based on… read more here.
Keywords: lymphoma kinase; anaplastic lymphoma; kinase; alk tkis ... See more keywords
Silibinin Overcomes EMT-Driven Lung Cancer Resistance to New-Generation ALK Inhibitors
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14246101
Abstract: Simple Summary Epithelial-to-mesenchymal transition (EMT) is a cellular plasticity program that can confer invasiveness, dissemination, and therapy resistance to cancer cells. Although inhibitors of this cellular process are expected to work as good “partners” for… read more here.
Keywords: alk tkis; generation alk; resistance; alk ... See more keywords